AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01460134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Study NCT03826186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional (loss-of-resistance technique) thoracic epidural placement
Description: Thoracic epidurals will be administered using the traditional loss-of resistance technique.
Study NCT03826186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CompuFlo thoracic epidural placement
Description: Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
Study NCT04797039 — intervention group
Intervention type: PROCEDURE
Intervention: MR guided cryoablation
Description: MR guided cryoablation of focal biopsy proven prostate cancer
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine+Mercaptopurine
Description: Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
Study NCT02975050 — intervention group
Intervention type: OTHER
Intervention: Location
Study NCT00972335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: This drug will be dosed at 10 mg orally DAILY for the duration of the study.
Study NCT00972335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
Study NCT04427865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prophylactic lactoferrin daily
Description: 200 mg oral lactoferrin daily
Study NCT01764711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin administration
Description: After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
Study NCT01398007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Camouflage syringe
Description: Dental anesthesia is administered using the camouflaged syringe.
Study NCT02750670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Type II anti-CD20 monoclonal antibody
Study NCT02750670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antineoplastic agent
Study NCT02750670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroid
Study NCT02750670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic Agent
Study NCT03796637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study NCT01001117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LensAR laser surgery
Description: Use of laser for cataract surgery
Study NCT01001117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco-emulsification cataract surgery
Description: Phaco-emulsification cataract surgery
Study NCT01499615 — intervention group
Intervention type: DEVICE
Intervention: cardiac monitor
Description: All children receive the same intervention which is the application of the 4 ekg electrodes
Study NCT05099796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection
Study NCT05099796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural steroid injection
Study NCT00648362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets 1 mg
Description: 1mg, single dose fasting
Study NCT00648362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl® Tablets 1 mg
Description: 1mg, single dose fasting
Study NCT02757144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets
Study NCT02757144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study NCT02757144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study NCT02757144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study NCT01785082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-C-Methacetin
Description: intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
Study NCT00897715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: 160 mg of rilonacept administered subcutaneously once a week for 12 weeks
Study NCT00897715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 160 mg of placebo administered subcutaneously once a week for 12 weeks
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine+Mercaptopurine
Description: Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine
Description: Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine+Mercaptopurine
Description: Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine
Description: Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine
Description: . Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
Study NCT04773366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local therapy
Description: Local therapy/wait and see. Group 4
Study NCT02500134 — intervention group
Intervention type: OTHER
Intervention: Optical coherence tomography study on limbus
Description: Optical coherence tomography study on limbus
Study NCT00681876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
Study NCT00681876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
Study NCT00681876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
Study NCT03575806 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE plus autologous Tcm immunotherapy
Description: TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro.
Study NCT03575806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE:transcatheter arterial chemoembolization.
Study NCT01829659 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Study NCT00768911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-322
Description: Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week
Study NCT02563366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: BM-MSCs are from third-party healthy volunteer donors.
Study NCT02563366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is the placebo of MSCs in this study.
Study NCT02926352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction Training
Description: Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
Study NCT02926352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extinction Training
Description: Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
Study NCT02926352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: 1064nm light used to modulate a biological function and induce a therapeutic effect.
Study NCT02926352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Low-Level Laser Therapy
Description: Placebo dose version of LLLT.
Study NCT02926352 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Level Laser Therapy
Description: Placebo dose version of LLLT.
Study NCT02160223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
Study NCT02160223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
Study NCT02434029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1mg orodispersible tablet twice daily
Study NCT02434029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orodispersible tablet twice daily
Study NCT00777920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Tablet administered orally once daily
Study NCT03585166 — intervention group
Intervention type: PROCEDURE
Intervention: lpaparoscopic hepatectomy
Description: laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
Study NCT03585166 — intervention group
Intervention type: PROCEDURE
Intervention: open hepatectomy
Description: open hepatectomy: open hepatectomy for hepatocellular carcinoma
Study NCT01872832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 and Placebo
Study NCT02860546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: One Arm Only (of TAS 102 plus nivolumab)
Study NCT02860546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: One Arm Only (of TAS 102 plus nivolumab)
Study NCT02245516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25% Ophthalmic Suspension
Description: KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study NCT04061837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitralStitch
Description: With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
Study NCT00666952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Decision Aid
Description: Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
Study NCT02245516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1.0% Ophthalmic Suspension
Description: KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study NCT02652975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24hour blood pressure
Description: 24 hour blood pressure measurement
Study NCT00768911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met
Study NCT00768911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
Study NCT00513240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoetin
Description: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
Study NCT00513240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~.
Study NCT01707290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, every 12 hours (q12h)
Study NCT00218712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Description: Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
Study NCT00218712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
Study NCT03458078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
Study NCT03458078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
Study NCT03458078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 5 MG/ML Injection
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
Study NCT00750425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib (RECENTIN TM, AZD2171)
Description: 20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
Study NCT00944099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
Study NCT00383253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 10%
Description: Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
Study NCT00383253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 25%
Description: Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
Study NCT00383253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 50%
Description: Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
Study NCT00383253 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: caloric restriction - Control
Description: Subjects maintained on their baseline caloric intake (caloric restriction = none)
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: administered via HandiHaler®
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: administered via HandiHaler®
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: administered via metered dose inhaler (MDI)
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: administered via metered dose inhaler (MDI)
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-MDI
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-MDI
Study NCT02242253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo HandiHaler®
Study NCT02364765 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
Study NCT01653535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast Track
Description: First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
Study NCT04781426 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg
Description: PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily
Study NCT01173120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abatacept combination product (ACP)
Description: Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)
Description: Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of vildagliptin 50 mg twice daily
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Patients continued their prescribed metformin dose, if applicable.
Study NCT02002221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued their prescribed metformin dose, if applicable.